您好,欢迎访问江苏省农业科学院 机构知识库!

Rational Development of Hypervalent Glycan Shield-Binding Nanoparticles with Broad-Spectrum Inhibition against Fatal Viruses Including SARS-CoV-2 Variants

文献类型: 外文期刊

作者: Li, Ying 1 ; Xu, Shuxin 1 ; Ye, Qing 2 ; Chi, Hang 2 ; Guo, Zhanchen 1 ; Chen, Jingran 1 ; Wu, Mei 2 ; Fan, Baochao 3 ; Li, Bin 3 ; Qin, Cheng-Feng 2 ; Liu, Zhen 1 ;

作者机构: 1.Nanjing Univ, Sch Chem & Chem Engn, State Key Lab Analyt Chem Life Sci, Nanjing 210023, Peoples R China

2.Beijing Inst Microbiol & Epidemiol, Dept Virol, State Key Lab Pathogen & Biosecur, AMMS, Beijing 100071, Peoples R China

3.Jiangsu Acad Agr Sci, Inst Vet Med, Key Lab Vet Biol Engn & Technol, Minist Agr, Nanjing 210014, Peoples R China

关键词: broad-spectrum antivirals; glycan shields; molecular imprinting; nanoparticles; severe acute respiratory syndrome coronavirus 2

期刊名称:ADVANCED SCIENCE ( 影响因子:17.521; 五年影响因子:18.939 )

ISSN:

年卷期:

页码:

收录情况: SCI

摘要: Infectious virus diseases, particularly coronavirus disease 2019, have posed a severe threat to public health, whereas the developed therapeutic and prophylactic strategies are seriously challenged by viral evolution and mutation. Therefore, broad-spectrum inhibitors of viruses are highly demanded. Herein, an unprecedented antiviral strategy is reported, targeting the viral glycan shields with hypervalent mannose-binding nanoparticles. The nanoparticles exhibit a unique double-punch mechanism, being capable of not only blocking the virus-receptor interaction but also inducing viral aggregation, thereby allowing for inhibiting the virus entry and facilitating the phagocytosis of viruses. The nanoparticles exhibit potent and broad-spectrum antiviral efficacy to multiple pseudoviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its major variants (D614G, N501Y, N439K, Delta 69-70, Delta, and Omicron; lentiviruses expressing only the spike proteins), as well as other vital viruses (human immunodeficiency virus 1 and Lassa virus), with apparent EC50 values around the 10(-9) m level. Significantly, the broad-spectrum inhibition of authentic viruses of both wild-type SARS-CoV-2 and Delta variants is confirmed. Therefore, this hypervalent glycan-shield targeting strategy opens new access to broad-spectrum viral inhibition.

  • 相关文献
作者其他论文 更多>>